What is HC Wainwright’s Forecast for CorMedix Q1 Earnings?

CorMedix Inc (NASDAQ:CRMD) – Research analysts at HC Wainwright cut their Q1 2026 EPS estimates for CorMedix in a note issued to investors on Thursday, March 5th. HC Wainwright analyst B. Folkes now anticipates that the company will earn $0.38 per share for the quarter, down from their prior forecast of $0.73. HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix’s Q2 2026 earnings at $0.21 EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at $0.43 EPS, FY2027 earnings at $0.01 EPS, FY2028 earnings at $0.38 EPS, FY2029 earnings at $1.08 EPS and FY2030 earnings at $1.55 EPS.

CorMedix (NASDAQ:CRMD) last posted its quarterly earnings data on Thursday, March 5th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.86 by ($0.70). CorMedix had a net margin of 52.31% and a return on equity of 52.30%. The firm had revenue of $128.62 million for the quarter, compared to the consensus estimate of $127.02 million. During the same period in the previous year, the firm posted $0.22 earnings per share. The business’s revenue was up 312.1% compared to the same quarter last year.

Several other brokerages have also recently weighed in on CRMD. Royal Bank Of Canada set a $13.00 price target on CorMedix and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Zacks Research cut shares of CorMedix from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of CorMedix in a research report on Wednesday, January 21st. Needham & Company LLC decreased their price target on shares of CorMedix from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. Finally, Leerink Partners reissued an “outperform” rating and set a $13.00 price target on shares of CorMedix in a research report on Friday. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

CorMedix Trading Up 1.5%

CRMD opened at $6.56 on Monday. The company has a quick ratio of 1.94, a current ratio of 2.11 and a debt-to-equity ratio of 0.36. CorMedix has a 52 week low of $5.60 and a 52 week high of $17.43. The stock has a market cap of $518.57 million, a PE ratio of 3.28 and a beta of 1.31. The business has a 50 day moving average of $7.93 and a 200-day moving average of $10.26.

CorMedix announced that its Board of Directors has initiated a share repurchase plan on Monday, February 2nd that authorizes the company to buyback $75.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 12.3% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.

Insider Activity at CorMedix

In related news, Director Alan W. Dunton sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $13.00, for a total value of $260,000.00. Following the completion of the transaction, the director directly owned 40,250 shares in the company, valued at $523,250. The trade was a 33.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Joseph Todisco sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $12.00, for a total value of $360,000.00. Following the completion of the transaction, the chief executive officer directly owned 509,496 shares in the company, valued at $6,113,952. This trade represents a 5.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 3.10% of the company’s stock.

Institutional Trading of CorMedix

Institutional investors have recently added to or reduced their stakes in the business. Financial Management Professionals Inc. purchased a new position in shares of CorMedix in the fourth quarter worth $25,000. Comerica Bank boosted its position in shares of CorMedix by 454.6% during the third quarter. Comerica Bank now owns 2,690 shares of the company’s stock valued at $31,000 after buying an additional 2,205 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of CorMedix during the second quarter valued at $42,000. Kestra Advisory Services LLC bought a new stake in CorMedix in the 4th quarter worth about $49,000. Finally, Caitong International Asset Management Co. Ltd raised its position in CorMedix by 666.6% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 4,385 shares of the company’s stock worth $51,000 after buying an additional 3,813 shares during the last quarter. 34.18% of the stock is currently owned by hedge funds and other institutional investors.

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.